191 research outputs found
Universal Surface Engineering of Transition Metals for Superior Electrocatalytic Hydrogen Evolution in Neutral Water
The development of low-cost hybrid water splitting-biosynthetic systems that mimic natural photosynthesis to achieve solar-to-chemical conversion is of great promise for future energy demands, but often limited by the kinetically sluggish hydrogen evolution reaction (HER) on the surface of nonprecious transition metal catalysts in neutral media. It is thus highly desirable to rationally tailor the reaction interface to boost the neutral HER catalytic kinetics. Herein, we report a general surface nitrogen modification of diverse transition metals (e.g. iron, cobalt, nickel, copper, and nickel-cobalt alloy), accomplished by a facile low-temperature ammonium carbonate treatment, for significantly improved hydrogen generation from neutral water. Various physicochemical characterization techniques including synchroton X-ray absorption spectroscopy (XAS) and theory modeling demonstrate that the surface nitrogen modification does not change the chemical composition of the underlying transition metals. Notably, the resulting nitrogen-modified nickel framework (N-Ni) exhibits an extremely low overpotential of 64 mV at 10 mA cm-2, which is, to our knowledge, the best among those nonprecious electrocatalysts reported for hydrogen evolution at pH 7. Out combined experimental results and density functional theory (DFT) calculations reveal that the surface electron-rich nitrogen simultaneously facilitates the initial adsorption of water via the electron-deficient H atom and the subsequent dissociation of the electron-rich HO-H bond via H transfer to N on the nickel surface, beneficial to the overall hydrogen evolution process
Intravenous bone marrow mononuclear cells transplantation in aged mice increases transcription of glucose transporter 1 and Na+/K+-ATPase at hippocampus followed by restored neurological functions
We recently reported that intravenous bone marrow mononuclear cell (BM-MNC) transplantation in stroke improves neurological function through improvement of cerebral metabolism. Cerebral metabolism is known to diminish with aging, and the reduction of metabolism is one of the presumed causes of neurological decline in the elderly. We report herein that transcription of glucose transporters, monocarboxylate transporters, and Na+/K+-ATPase is downregulated in the hippocampus of aged mice with impaired neurological functions. Intravenous BM-MNC transplantation in aged mice stimulated the transcription of glucose transporter 1 and Na+/K+-ATPase Ξ±1 followed by restoration of neurological function. As glucose transporters and Na+/K+-ATPases are closely related to cerebral metabolism and neurological function, our data indicate that BM-MNC transplantation in aged mice has the potential to restore neurological function by activating transcription of glucose transporter and Na+/K+-ATPase. Furthermore, our data indicate that changes in transcription of glucose transporter and Na+/K+-ATPase could be surrogate biomarkers for age-related neurological impairment as well as quantifying the efficacy of therapies
Recommended from our members
Accelerated Oxygen Atom Transfer and CβH Bond Oxygenation by Remote Redox Changes in Fe_3Mn-Iodosobenzene Adducts
We report the synthesis, characterization, and reactivity of [Lfe_3(PhPz)_3OMn(^sPhIO)][OTf]_x (3: x=2; 4: x=3), where 4 is one of very few examples of iodosobenzeneβmetal adducts characterized by X-ray crystallography. Access to these rare heterometallic clusters enabled differentiation of the metal centers involved in oxygen atom transfer (Mn) or redox modulation (Fe). Specifically, ^(57)Fe MΓΆssbauer and X-ray absorption spectroscopy provided unique insights into how changes in oxidation state (Fe^(III)_2Fe^(II)Mn^(II) vs. Fe^(III)_3Mn^(II)) influence oxygen atom transfer in tetranuclear Fe_3Mn clusters. In particular, a one-electron redox change at a distal metal site leads to a change in oxygen atom transfer reactivity by ca. two orders of magnitude
Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells
Defects in epigenetic pathways are key drivers of oncogenic cell proliferation. We developed a LSD1/HDAC6 multitargeting inhibitor (iDual), a hydroxamic acid analogue of the clinical candidate LSD1 inhibitor GSK2879552. iDual inhibits both targets with IC50 values of 540, 110, and 290 nM, respectively, against LSD1, HDAC6, and HDAC8. We compared its activity to structurally similar control probes that act by HDAC or LSD1 inhibition alone, as well as an inactive null compound. iDual inhibited the growth of leukemia cell lines at a higher level than GSK2879552 with micromolar IC50 values. Dual engagement with LSD1 and HDAC6 was supported by dose dependent increases in substrate levels, biomarkers, and cellular thermal shift assay. Both histone methylation and acetylation of tubulin were increased, while acetylated histone levels were only mildly affected, indicating selectivity for HDAC6. Downstream gene expression (CD11b, CD86, p21) was also elevated in response to iDual treatment. Remarkably, iDual synergized with doxorubicin, triggering significant levels of apoptosis with a sublethal concentration of the drug. While mechanistic studies did not reveal changes in DNA repair or drug efflux pathways, the expression of AGPAT9, ALOX5, BTG1, HIPK2, IFI44L, and LRP1, previously implicated in doxorubicin sensitivity, was significantly elevated
Recommended from our members
Tetranuclear [Mn^(III)Mn_3^(IV)O_4] Complexes as Spectroscopic Models of the S_2 State of the Oxygen Evolving Complex in Photosystem II
Despite extensive biochemical, spectroscopic, and computational studies, the mechanism of biological water oxidation by the oxygen evolving complex (OEC) of Photosystem II remains a subject of significant debate. Mechanistic proposals are guided by the characterization of reaction intermediates such as the S_2 state, which features two characteristic EPR signals at g = 2 and g = 4.1. Two nearly isoenergetic structural isomers have been proposed as the source of these distinct signals, but relevant structureβelectronic structure studies remain rare. Herein, we report the synthesis, crystal structure, electrochemistry, XAS, magnetic susceptibility, variable temperature CW-EPR, and pulse EPR data for a series of [Mn^(III)Mn_3^(IV)O_4] cuboidal complexes as spectroscopic models of the S_2 state of the OEC. Resembling the oxidation state and EPR spectra of the S_2 state of the OEC, these model complexes show two EPR signals, a broad low field signal and a multiline signal, that are remarkably similar to the biological system. The effect of systematic changes in the nature of the bridging ligands on spectroscopy were studied. Results show that the electronic structure of tetranuclear Mn complexes is highly sensitive to even small geometric changes and the nature of the bridging ligands. Our model studies suggest that the spectroscopic properties of the OEC may also react very sensitively to small changes in structure; the effect of protonation state and other reorganization processes need to be carefully assessed
Molecular Mixed-Metal Manganese Oxido Cubanes as Precursors to Heterogeneous Oxygen Evolution Catalysts
Well-defined mixed-metal [CoMn_3O_4] and [NiMn_3O_4] cubane complexes were synthesized and used as precursors for heterogeneous oxygen evolution reaction (OER) electrocatalysts. The discrete clusters were dropcasted onto glassy carbon (GC) and indium tin oxide (ITO) electrodes, and the OER activities of the resulting films were evaluated. The catalytic surfaces were analyzed by various techniques to gain insight into the structure-function relationships of the electrocatalystsβ heterometallic composition. Depending on preparation conditions, the Co-Mn oxide was found to change metal composition during catalysis, while the NiβMn oxides maintained the NiMn_3 ratio. XAS studies provided structural insights indicating that the electrocatalysts are different from the molecular precursors, but that the original NiMn_3O_4 cubane-like geometry was maintained in the absence of thermal treatment (2-Ni). In contrast, the thermally generated 3-Ni develops an oxide-like extended structure. Both 2-Ni and 3-Ni undergo structural changes upon electrolysis, but they do not convert into the same material. The observed structural motifs in these heterogeneous electrocatalysts are reminiscent of the biological oxygen-evolving complex in Photosystem II, including the MMn_3O_4 cubane moiety. The reported studies demonstrate the use of discrete heterometallic oxide clusters as precursors for heterogeneous water oxidation catalysts of novel composition and the distinct behavior of two sets of mixed metal oxides
Activation of neurogenesis in the hippocampus is a novel therapeutic target for Alzheimer's disease
Highlights: Targeting single mechanisms of physiological (aging) and pathological (neurodegeneration) loss of function in the brain may not be sufficient. Cellβcell interactions between transplanted adult stem cells and resident cells via gap junctions have the potential to support the aging or diseased brain. These cellβcell interactions can also increase hippocampal neurogenesis. This may be a novel therapeutic strategy for Alzheimer's disease and other neurodegenerative diseases that could be applied alongside any established treatments
Multitargeting epi-epi drugs for multidrug reistance
Epigenetic therapy is now a clinical reality with eight approved drugs that target
DNA methyltransferases, histone deacetylases (HDACs) and lysine
methyltransferases. A further recent development is the concept of epigenetic
multitargeting through the rational design of novel agents that combine the
inhibition of an epigenetic pathway with a second non-epigenetic target and five
such compounds have advanced to clinical development.
We are investigating the even newer concept of βepi-epiβ drugs that inhibit two
separate epigenetic pathways. Such dual targeting agents have the potential to
achieve higher efficacy against proliferating cancer cells while reducing tunor
resistance. In this presentation, we report a selective dual histone deacetylase and
demethylase inhibitor with an IC50
LSD1 respectively. The compound was biologically profiled together with control
compounds that were either single inhibitors or inactive against either enzyme. The
dua inhibitor was active against a panel of leukemia cell lines at a micromolar level
and induced apoptosis. Target engagement asays such as CETSA were employed
to confirm the inhibition of HDAC6 and LSD1 in cells. Further experiments were
carried out to identify synergistic effects with clinically approved agents and
promising results were observed with doxorubicin
ΠΠΎΡΡΠΎΡΠΈ Π»ΠΈ Π³ΡΠ°Π½ΠΈΡΠ° ΠΈΠ·ΠΌΠ΅ΡΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΠ³ ΠΈ Π°Π½ΡΠΈΠΌΠ΅ΡΠ°ΡΡΠ°ΡΡΠΊΠΎΠ³ Π΅ΡΠ΅ΠΊΡΠ° ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈΡ ΠΈΠ½Ρ ΠΈΠ±ΠΈΡΠΎΡΠ° Ρ ΠΈΡΡΠΎΠ½ Π΄Π΅Π°ΡΠ΅ΡΠΈΠ»Π°Π·Π΅ 6 ΠΊΠΎΠ΄ ΡΠΎΠ»ΠΈΠ΄Π½ΠΈΡ ΡΡΠΌΠΎΡΠ°?
Academia and industry make an extensive effort to discover selective histone deacetylase 6 inhibitors (HDAC6i) which could be delivered to the patients. These attempts are partially obscured by inconsistency in preclinical data regarding the cellular and biochemical changes upon treatment of solid tumours with HDAC6i. In this study, we present computational design, synthesis of three novel HDAC6 inhibitors along with their in vitro pharmacological profile against zinc-dependent HDACs. The in vitro anticancer effects of the synthesized compounds were examined on four types of cancer cell lines, human breast cancer cell lines (MDA-MB-231 and MCF-7) as well as human melanoma cells (A-375 and 518A2). It was found that the synthesized compounds induce apoptosis in high concentrations (IC50 >30 ΞΌM) nonetheless, the observed morphological changes of studied cell lines during cell viability assay prompted us to examine their antimetastatic properties. Novel compound MBDR-4 significantly reduces migration and invasiveness of the MDA-MB-231 and A375 cancer cell lines at subapoptotic concentration (5 ΞΌM), which open new avenues for redirecting drug development of selective HDAC6 inhibitors as adjuvant chemotherapeutics, with antimetastatic effects.ΠΡΡΡΠ°ΠΆΠΈΠ²Π°ΡΠΈ ΡΡΠ΅Π½ΡΡΠ½ΠΎ ΡΠ»Π°ΠΆΡ Π²Π΅Π»ΠΈΠΊΠ΅ Π½Π°ΠΏΠΎΡΠ΅ Ρ ΠΈΡΠΏΠΈΡΠΈΠ²Π°ΡΠ΅ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈΡ
ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠ° Ρ
ΠΈΡΡΠΎΠ½ Π΄Π΅Π°ΡΠ΅ΡΠΈΠ»Π°Π·Π΅ 6 (HDAC6i) 1,2 ΠΊΠΎΡΠΈ Π±ΠΈ ΠΌΠΎΠ³Π»ΠΈ Π΄Π° Π½Π°ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΡ
ΠΏΡΠΈΠΌΠ΅Π½Ρ 3 . ΠΠ²Π° ΠΈΡΡΡΠ°ΠΆΠΈΠ²Π°ΡΠ° ΡΡ Π΄Π΅Π»ΠΈΠΌΠΈΡΠ½ΠΎ ΠΎΡΠ΅ΠΆΠ°Π½Π° ΡΡΠ»Π΅Π΄ Π½Π΅ΠΊΠΎΠ½Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΈΡ
ΠΏΡΠ΅ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΈΡ
ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠ° ΠΎ ΡΠ΅Π»ΠΈΡΡΠΊΠΈΠΌ ΠΈ Π±ΠΈΠΎΡ
Π΅ΠΌΠΈΡΡΠΊΠΈΠΌ ΠΏΡΠΎΠΌΠ΅Π½Π°ΠΌΠ° Π½Π°ΠΊΠΎΠ½
ΡΡΠ΅ΡΠΌΠ°Π½Π° ΡΠΎΠ»ΠΈΠ΄Π½ΠΈΡ
ΡΡΠΌΠΎΡΠ° HDAC6i(4,5). ΠΠ°ΡΠ° ΡΡΡΠ΄ΠΈΡΠ° ΠΎΠ±ΡΡ
Π²Π°ΡΠ° ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΡΠΊΠΈ Π΄ΠΈΠ·Π°ΡΠ½ ΠΈ ΡΠΈΠ½ΡΠ΅Π·Ρ ΡΡΠΈ Π½ΠΎΠ²Π° HDAC6
ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠ°, Π·Π°ΡΠ΅Π΄Π½ΠΎ ΡΠ° in vitro Π΅Π½Π·ΠΈΠΌΡΠΊΠΈΠΌ ΠΈΡΠΏΠΈΡΠΈΠ²Π°ΡΠ΅ΠΌ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π½Π°
ΡΡΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ·ΠΎΡΠΎΡΠΌΠ°ΠΌΠ° HDAC Π΅Π½Π·ΠΈΠΌΠΈΠΌΠ°. ΠΠ½ΡΠΈΠ½Π΅ΠΎΠΏΠ»Π°ΡΡΠΈΡΠ°Π½ Π΅ΡΠ΅ΠΊΠ°Ρ ΡΠΈΠ½ΡΠ΅-
ΡΠΈΡΠ°Π½ΠΈΡ
ΡΠ΅Π΄ΠΈΡΠ΅ΡΠ° ΡΠ΅ ΠΈΡΠΏΠΈΡΠ°Π½ in vitro Π½Π° ΡΠ΅ΡΠΈΡΠΈ ΡΠΈΠΏΠ° ΡΠ΅Π»ΠΈΡΠ° ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ°,
Ρ
ΡΠΌΠ°Π½ΠΈΠΌ ΡΠ΅Π»ΠΈΡΠ°ΠΌΠ° ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ° Π΄ΠΎΡΠΊΠ΅ (MDA-MB-231 ΠΈ MCF-7) ΠΈ Ρ
ΡΠΌΠ°Π½ΠΈΠΌ ΡΠ΅-
Π»ΠΈΡΠ°ΠΌΠ° ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠ° (A-375 ΠΈ 518A2). Π£ΡΠ²ΡΡΠ΅Π½ΠΎ ΡΠ΅ Π΄Π° ΡΠΈΠ½ΡΠ΅ΡΠΈΡΠ°Π½Π° ΡΠ΅Π΄ΠΈΡΠ΅ΡΠ°
ΠΈΠ½Π΄ΡΠΊΡΡΡ Π°ΠΏΠΎΠΏΡΠΎΠ·Ρ ΠΏΡΠΈ Π²ΠΈΡΠΎΠΊΠΈΠΌ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡΠ°ΠΌΠ° (IC 50 >30 ΞΌM). ΠΡΡΠΎΠ²ΡΠ΅ΠΌΠ΅-
Π½ΠΎ ΡΠ΅ ΡΠΎΡΠ΅Π½ΠΎ Π΄Π° ΠΎΠ²Π° ΡΠ΅Π΄ΠΈΡΠ΅ΡΠ° Π΄ΠΎΠ²ΠΎΠ΄Π΅ ΠΈ Π΄ΠΎ ΠΌΠΎΡΡΠΎΠ»ΠΎΡΠΊΠΈΡ
ΠΏΡΠΎΠΌΠ΅Π½Π° Π½Π° ΡΡΠ΅-
ΡΠΈΡΠ°Π½ΠΈΠΌ ΡΠ΅Π»ΠΈΡΠ°ΠΌΠ° ΡΠΎΠΊΠΎΠΌ ΠΈΠ·Π²ΠΎΡΠ΅ΡΠ° ΡΠ΅ΡΡΠ° Π²ΠΈΠ°Π±ΠΈΠ»Π½ΠΎΡΡΠΈ ΡΡΠΎ Π½Π°Ρ ΡΠ΅ ΡΡΠΌΠ΅ΡΠΈ-
Π»ΠΎ ΠΊΠ° ΠΈΡΠΏΠΈΡΠΈΠ²Π°ΡΡ ΡΠΈΡ
ΠΎΠ²ΠΈΡ
Π°Π½ΡΠΈΠΌΠ΅ΡΠ°ΡΡΠ°ΡΡΠΊΠΈΡ
ΠΎΡΠΎΠ±ΠΈΠ½Π°. ΠΠ΅Π΄ΠΈΡΠ΅ΡΠ΅ MBDR-4
ΡΠ½Π°ΠΆΠ½ΠΎ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠ° ΠΌΠΈΠ³ΡΠ°ΡΠΈΡΡ ΠΈ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΡΡ MDA-MB-231 ΠΈ A375 ΡΠ΅Π»ΠΈΡΠ° ΠΊΠ°Π½-
ΡΠ΅ΡΠ° Π½Π° ΡΡΠ±Π°ΠΏΠΎΠΏΡΠΎΡΡΠΊΠΎΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡΠΈ (5 ΞΌM), ΡΡΠΎ ΠΎΡΠ²Π°ΡΠ° Π½ΠΎΠ²Π΅ ΠΌΠΎΠ³ΡΡΠ½ΠΎΡΡΠΈ
Π·Π° ΠΈΡΡΡΠ°ΠΆΠΈΠ²Π°ΡΠ΅ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈΡ
HDAC6 ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠ° ΠΊΠ°ΠΎ Π°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΈΡ
Ρ
Π΅ΠΌΠΎΡΠ΅-
ΡΠ°ΠΏΠ΅ΡΡΠΈΠΊΠ° ΡΠ° Π°Π½ΡΠΈΠΌΠ΅ΡΠ°ΡΡΠ°ΡΡΠΊΠΈΠΌ Π΅ΡΠ΅ΠΊΡΠΎΠΌ.ΠΠ°Π½ΡΠ΅ΡΠΎΠ»ΠΎΡΠΊΠ° ΡΠ΅ΠΊΡΠΈΡΠ° Π‘ΡΠΏΡΠΊΠΎΠ³ Π»Π΅ΠΊΠ°ΡΡΠΊΠΎΠ³ Π΄ΡΡΡΡΠ²Π°
Serbian Medical Society Oncology Section
ΠΠ΅ΠΎΠ³ΡΠ°Π΄, Π½ΠΎΠ²Π΅ΠΌΠ±Π°Ρ 2019 / Belgrade, November 2019
ΠΠΠΠΠ ΠΠΠΠ¦ΠΠ ΠΠΠΠ¨ΠΠ
Π‘ΠΠΠ¦ΠΠΠ Π‘ΠΠ
ANNALS OF ONCOLOGY
SECTION
ΠΠ±ΠΎΡΠ½ΠΈΠΊ Π°ΠΏΡΡΡΠ°ΠΊΠ°ΡΠ° / Abstract Boo
- β¦